GammaCan: data show effectiveness of IVIG in malignant melanoma

By Lisa Kerner

Charlotte, N.C., Sept. 19 - GammaCan International, Inc. said top line results of its phase 2 efficacy and safety study of IVIG (GCAN101) suggest that IVIG may lead to stabilization of malignant melanoma in some patients and that IVIG therapy appears to be safe.

The results will be presented at the 5th Annual Congress on Autoimmunity in Sorrento, Italy, in November.

"This study is part of our larger GCAN 101 open label phase 2 study which also includes prostate and colon cancer patients," the director of medical and scientific affairs, Jacob Nusbacher, said in a news release from the Kiryat Ono, Israel-based pharmaceutical company.

"These results give us further impetus to develop VitiGam, our next generation anti-melanoma immunoglobulin therapy."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.